Masimo (NASDAQ:MASI) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.66. The company issued revenue guidance of $836.0 million, compared to the consensus revenue estimate of $832.07 million.
A number of research firms have recently weighed in on MASI. Zacks Investment Research cut Masimo from a buy rating to a hold rating in a report on Wednesday, February 7th. BidaskClub lowered shares of Masimo from a hold rating to a sell rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus reiterated a buy rating and set a $108.00 price objective on shares of Masimo in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $104.60.
Masimo (MASI) traded up $0.44 during midday trading on Tuesday, hitting $86.08. 689,376 shares of the company were exchanged, compared to its average volume of 508,637. Masimo has a fifty-two week low of $80.69 and a fifty-two week high of $104.71. The firm has a market capitalization of $4,450.00, a price-to-earnings ratio of 13.64, a PEG ratio of 3.22 and a beta of 0.85.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.